Cargando…
Combination Therapy With Adalimumab Plus Intensive Granulocyte and Monocyte Adsorptive Apheresis in Patients With Refractory Ulcerative Colitis
BACKGROUND: The efficacy and safety of combination therapy with adalimumab (ADA) plus intensive granulocyte and monocyte adsorptive apheresis (GMA) (two sessions per week) for the treatment of refractory ulcerative colitis (UC) have not been previously evaluated. METHODS: This retrospective study ev...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elmer Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4596271/ https://www.ncbi.nlm.nih.gov/pubmed/26491502 http://dx.doi.org/10.14740/jocmr2333w |
_version_ | 1782393734008143872 |
---|---|
author | Tanida, Satoshi Mizoshita, Tsutomu Nishie, Hirotada Ozeki, Keiji Katano, Takahito Kubota, Eiji Kataoka, Hiromi Kamiya, Takeshi Joh, Takashi |
author_facet | Tanida, Satoshi Mizoshita, Tsutomu Nishie, Hirotada Ozeki, Keiji Katano, Takahito Kubota, Eiji Kataoka, Hiromi Kamiya, Takeshi Joh, Takashi |
author_sort | Tanida, Satoshi |
collection | PubMed |
description | BACKGROUND: The efficacy and safety of combination therapy with adalimumab (ADA) plus intensive granulocyte and monocyte adsorptive apheresis (GMA) (two sessions per week) for the treatment of refractory ulcerative colitis (UC) have not been previously evaluated. METHODS: This retrospective study evaluated the 10-week efficacy of combination therapy with ADA plus intensive GMA on refractory UC patients, on clinical outcomes over 52 weeks under subsequent maintenance monotherapy of ADA, and the effect of combined azathioprine (AZA) with ADA at failure to achieve clinical remission at 10 weeks and at flare-up by 52 weeks. Ten patients were given initial combination therapy of ADA (160/80/40 mg every other week) plus intensive GMA. One patient received total colectomy because of poor response. RESULTS: Of nine patients who received this combination therapy, 55.6% displayed cumulative clinical remission at 10 weeks and 33.3% displayed such remission at 52 weeks under subsequent maintenance monotherapy of ADA. The percentage of patients with mucosal healing at 10 weeks (endoscopy subscore ≤ 1) was 66.7%. Adverse events were observed in three patients (pneumonia, cerebral infarction and headache). CONCLUSION: It was concluded that combination therapy with ADA plus intensive GMA is useful for induction of clinical remission in refractory UC patients, and is well tolerated. |
format | Online Article Text |
id | pubmed-4596271 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Elmer Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-45962712015-10-21 Combination Therapy With Adalimumab Plus Intensive Granulocyte and Monocyte Adsorptive Apheresis in Patients With Refractory Ulcerative Colitis Tanida, Satoshi Mizoshita, Tsutomu Nishie, Hirotada Ozeki, Keiji Katano, Takahito Kubota, Eiji Kataoka, Hiromi Kamiya, Takeshi Joh, Takashi J Clin Med Res Original Article BACKGROUND: The efficacy and safety of combination therapy with adalimumab (ADA) plus intensive granulocyte and monocyte adsorptive apheresis (GMA) (two sessions per week) for the treatment of refractory ulcerative colitis (UC) have not been previously evaluated. METHODS: This retrospective study evaluated the 10-week efficacy of combination therapy with ADA plus intensive GMA on refractory UC patients, on clinical outcomes over 52 weeks under subsequent maintenance monotherapy of ADA, and the effect of combined azathioprine (AZA) with ADA at failure to achieve clinical remission at 10 weeks and at flare-up by 52 weeks. Ten patients were given initial combination therapy of ADA (160/80/40 mg every other week) plus intensive GMA. One patient received total colectomy because of poor response. RESULTS: Of nine patients who received this combination therapy, 55.6% displayed cumulative clinical remission at 10 weeks and 33.3% displayed such remission at 52 weeks under subsequent maintenance monotherapy of ADA. The percentage of patients with mucosal healing at 10 weeks (endoscopy subscore ≤ 1) was 66.7%. Adverse events were observed in three patients (pneumonia, cerebral infarction and headache). CONCLUSION: It was concluded that combination therapy with ADA plus intensive GMA is useful for induction of clinical remission in refractory UC patients, and is well tolerated. Elmer Press 2015-11 2015-09-25 /pmc/articles/PMC4596271/ /pubmed/26491502 http://dx.doi.org/10.14740/jocmr2333w Text en Copyright 2015, Tanida et al. http://creativecommons.org/licenses/by/2.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Tanida, Satoshi Mizoshita, Tsutomu Nishie, Hirotada Ozeki, Keiji Katano, Takahito Kubota, Eiji Kataoka, Hiromi Kamiya, Takeshi Joh, Takashi Combination Therapy With Adalimumab Plus Intensive Granulocyte and Monocyte Adsorptive Apheresis in Patients With Refractory Ulcerative Colitis |
title | Combination Therapy With Adalimumab Plus Intensive Granulocyte and Monocyte Adsorptive Apheresis in Patients With Refractory Ulcerative Colitis |
title_full | Combination Therapy With Adalimumab Plus Intensive Granulocyte and Monocyte Adsorptive Apheresis in Patients With Refractory Ulcerative Colitis |
title_fullStr | Combination Therapy With Adalimumab Plus Intensive Granulocyte and Monocyte Adsorptive Apheresis in Patients With Refractory Ulcerative Colitis |
title_full_unstemmed | Combination Therapy With Adalimumab Plus Intensive Granulocyte and Monocyte Adsorptive Apheresis in Patients With Refractory Ulcerative Colitis |
title_short | Combination Therapy With Adalimumab Plus Intensive Granulocyte and Monocyte Adsorptive Apheresis in Patients With Refractory Ulcerative Colitis |
title_sort | combination therapy with adalimumab plus intensive granulocyte and monocyte adsorptive apheresis in patients with refractory ulcerative colitis |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4596271/ https://www.ncbi.nlm.nih.gov/pubmed/26491502 http://dx.doi.org/10.14740/jocmr2333w |
work_keys_str_mv | AT tanidasatoshi combinationtherapywithadalimumabplusintensivegranulocyteandmonocyteadsorptiveapheresisinpatientswithrefractoryulcerativecolitis AT mizoshitatsutomu combinationtherapywithadalimumabplusintensivegranulocyteandmonocyteadsorptiveapheresisinpatientswithrefractoryulcerativecolitis AT nishiehirotada combinationtherapywithadalimumabplusintensivegranulocyteandmonocyteadsorptiveapheresisinpatientswithrefractoryulcerativecolitis AT ozekikeiji combinationtherapywithadalimumabplusintensivegranulocyteandmonocyteadsorptiveapheresisinpatientswithrefractoryulcerativecolitis AT katanotakahito combinationtherapywithadalimumabplusintensivegranulocyteandmonocyteadsorptiveapheresisinpatientswithrefractoryulcerativecolitis AT kubotaeiji combinationtherapywithadalimumabplusintensivegranulocyteandmonocyteadsorptiveapheresisinpatientswithrefractoryulcerativecolitis AT kataokahiromi combinationtherapywithadalimumabplusintensivegranulocyteandmonocyteadsorptiveapheresisinpatientswithrefractoryulcerativecolitis AT kamiyatakeshi combinationtherapywithadalimumabplusintensivegranulocyteandmonocyteadsorptiveapheresisinpatientswithrefractoryulcerativecolitis AT johtakashi combinationtherapywithadalimumabplusintensivegranulocyteandmonocyteadsorptiveapheresisinpatientswithrefractoryulcerativecolitis |